"Can my doctor prescribe it?" has three different answers depending on what it is. An approved peptide drug can be prescribed, for its label use and beyond it. A compounded peptide can be prescribed, but a pharmacy may only fill it if the ingredient passes tests written into federal law. A research-chemical vial cannot be prescribed into legitimacy at all. This page sets out the three routes from the statute and FDA's own pages, and where telehealth changes nothing and where it changes something.
The legal position of peptides generally is on our are peptides legal page; the two kinds of compounding pharmacy on our 503A vs 503B page; what clinics actually sell under the name on our peptide therapy page. Nothing here is legal or medical advice for any individual.
Route 1: an approved peptide drug
More than 80 peptide drugs carry FDA approval. Each has a label stating its indication, dose and warnings, and each is a prescription product. Examples on this site: tesamorelin (Egrifta), hCG (Pregnyl, Novarel), mecasermin (Increlex — compared with its research analogue on our Increlex vs IGF-1 LR3 page), bremelanotide (Vyleesi) and the teriparatide family. The full census is on our FDA-approved peptides page.
A prescriber is not confined to the label. FDA's patient page on off-label use says that once a drug is approved, "healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate" (FDA, content current as of 5 February 2018, read 22 October 2026). hCG alongside testosterone therapy, set out on our hCG for men page, is the best-known peptide example: common, off-label, and resting on small studies rather than an approval.
Off-label is a statement about the use, not the product. The drug is still the approved, manufactured, labelled product.
Route 2: a compounded peptide
Compounding is a pharmacy preparing a drug for one patient. Federal law exempts such a drug from the approval requirement only on conditions, set out in section 503A of the Food, Drug, and Cosmetic Act (21 U.S.C. 353a, read 22 October 2026). The first is the prescription: the drug must be compounded "for an identified individual patient based on the receipt of a valid prescription order", by a licensed pharmacist or physician. Without a prescription there is no 503A route.
The second is the ingredient. A bulk drug substance qualifies only if it:
| Test | What the statute says |
|---|---|
| (I) Monograph | Complies with an applicable USP or National Formulary monograph, if one exists |
| (II) Approved component | If there is no monograph, is a component of a drug FDA has approved |
| (III) Bulks list | If neither, appears on the list FDA makes by regulation (the "503A bulks list") |
And, whichever test it passes, the bulk substance must be made by an establishment registered with FDA and accompanied by a valid certificate of analysis. The pharmacy may not compound anything on FDA's list of drugs withdrawn for being unsafe or not effective, and may not regularly compound essential copies of a commercially available drug.
Read against those tests, the common clinic peptides fall into three groups:
| Group | Examples | Where it stands |
|---|---|---|
| Component of an approved drug | Tesamorelin, hCG, bremelanotide, sermorelin (Geref, approved 1990, since discontinued) | Test (II) is available; copies of a product still on the market face the essential-copy limit |
| In FDA's category 2 (significant safety risks) | Kisspeptin-10 (503A); GHRP-2, GHRP-6, ipamorelin acetate (503B); ibutamoren (both) | Not on the list, and outside category 1 — the group FDA does not intend to act against while it evaluates; FDA has identified these as presenting significant safety risks |
| Nominated, then withdrawn | BPC-157, TB-500, CJC-1295, AOD-9604, selank, semax, epitalon, MOTS-c, KPV, LL-37, DSIP, dihexa, pegylated MGF, melanotan II, thymosin alpha 1, GHK-Cu for injection | No monograph, no approved component, not on the list — none of the three tests currently applies |
The category 2 and withdrawn lists are FDA's, read 13 September 2026 and indexed with dates on our category 2 page. Category 2 is a compounding classification, not a controlled-substance schedule. A withdrawn nomination is neither a ban nor a clearance: it means no evaluation produced a listing, and FDA's advisory committee voted on several of these in July 2026 (see our peptide therapy page).
What the table cannot say is what any individual pharmacy does. Some sell compounded semax or BPC-157 openly; whether they cite a basis in the statute, and whether their state board agrees, is outside what a public record shows. The statute says what qualifies; enforcement is a separate question, documented on our FDA warning letters tracker.
Route 3: there is no route 3
A vial sold "for research use only, not for human consumption" is not a drug product made for a patient. It arrives without a prescription, from a seller that is not a pharmacy, usually without the registered-establishment and certificate-of-analysis chain the statute requires of a compounding ingredient. A doctor writing a note does not change what is in it or where it came from. Why that labelling exists, and what it does and does not protect, is on our research-use-only page.
Where telehealth fits
Telehealth changes who examines the patient and how. It does not change any of the three routes above: the same approved products, the same off-label rule, the same 503A ingredient tests apply whether the visit was in a room or on a screen.
The one federal telehealth prescribing rule that gets cited is the DEA's. Under the Ryan Haight Act, prescribing a controlled substance generally required an in-person evaluation; the COVID-era flexibilities waived that, and DEA and HHS have extended them a fourth time, through 31 December 2026 (Federal Register, 31 December 2025). That rule is about controlled medications; most peptides are not in that category, so it neither permits nor forbids a telehealth peptide prescription. For non-controlled drugs, what counts as an adequate examination and a valid prescriber–patient relationship is set by the medical practice law of the state where the patient is.
What this means in practice for a reader comparing services: a telehealth prescription for a compounded peptide is only as sound as the ingredient route behind it. The question worth asking a provider is not "is the doctor licensed?" but "which pharmacy compounds it, and which of the three tests does the ingredient pass?" Costs for the services that publish them are on our peptide cost page.
What this page does not settle
- Individual state law. Practice standards, telehealth rules and pharmacy board positions vary by state; none is summarised here.
- FDA's next step. The 503A bulks list is still being built; a listing, a category change or a rule would change the middle table. FDA's interim peptide policy was still unpublished when this page was written.
- Whether a given prescription is appropriate. That is a clinical judgement for the prescriber, and nothing here substitutes for it.
Sources and dates
- 21 U.S.C. 353a (FD&C Act section 503A), Cornell Legal Information Institute text — read 22 October 2026.
- FDA, "Understanding Unapproved Use of Approved Drugs 'Off Label'", content current as of 5 February 2018 — read 22 October 2026.
- DEA/HHS, "Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications", Federal Register document 2025-24123, published 31 December 2025, effective 1 January–31 December 2026 — abstract and dates read 22 October 2026.
- FDA category 2 and withdrawn-nomination tables for 503A/503B bulk substances, content current as of 22 April 2026 — read 13 September 2026 (see our category 2 page for the full record).